Lumentum stock ticks up after GF lifts target to $765 and flags 2027 optics ‘inflection’

Lumentum stock ticks up after GF lifts target to $765 and flags 2027 optics ‘inflection’

February 23, 2026

New York, Feb 23, 2026, 11:31 (ET) — Regular session underway

  • Lumentum shares claw back about 1% in late-morning trading, recovering after slipping ahead of the open.
  • GF Securities bumps its price target up to $765, sticking with its Buy rating.
  • Shares of Applied Optoelectronics pop, while Coherent and Nvidia barely move.

Lumentum Holdings Inc (LITE.O) picked up nearly 1%, trading around $674.10 by late morning Monday, after a fresh analyst note kept attention fixed on the company’s optics ramp tied to AI. GF Securities upped its price target to $765, calling 2027 a “key inflection year.” Analyst Jeff Pu now sees CPO/NPO laser revenue landing at $124 million for 2026, then jumping to $500 million in 2027 and $1.7 billion in 2028. Applied Optoelectronics climbed roughly 5%. Shares of Coherent and Nvidia barely budged. GuruFocus

This call is drawing attention since Lumentum has become something of a real-time case study for how quickly major data-center operators are moving to upgrade for AI. Hopes around the stock have hinged on the bet that the rush for speedier connections will pull spending from legacy telecom projects and redirect it toward advanced optical equipment. The catch: timing is anything but clear-cut.

Everything depends on when co-packaged optics finally hit—put simply, that’s about getting optical engines right up next to switching chips to shave power and help data zip. “Near-packaged optics” comes into play too. If rollouts get delayed, revenue slips in tandem, and the shares—already behaving like a high-beta stand-in for AI infrastructure spending—can lurch in either direction. Marvell Technology

Lumentum makes optical components and photonic products for telecom, enterprise, and data center networks, plus commercial lasers for manufacturing and other uses. Traders are now working to gauge just how much of the upcoming buildout drives demand for optics—and which companies, exactly, get a piece of the action.

Lumentum turned in net revenue of $665.5 million for its fiscal second quarter, with non-GAAP diluted EPS landing at $1.67. Looking ahead, the company set its third-quarter revenue outlook in a range of $780 million to $830 million. CEO Michael Hurlston put it bluntly: they’re “only at the starting line” when it comes to optical circuit switches and co-packaged optics—gear designed to keep traffic moving inside high-speed networks. Lumentum Investor Relations

Optical circuit switches, or OCS, route light signals without turning them back into electricity—saving power and cutting latency. That’s been a selling point for cloud providers assembling denser AI clusters, and it’s become central to the current debate over how quickly these new architectures jump from lab experiments to actual data center racks.

The bear case is clear enough: a pause in hyperscaler spending, or delays tied to co-packaged design—be it manufacturing hiccups, heat issues, or standards snags—and suddenly the ramp happens later, maybe doesn’t look as big. After such a steep rally, the stock could be left out on a limb.

The next major event for traders lands March 17: Lumentum is slated to hold its investor briefing at the Optical Fiber Communication Conference and Exhibition (OFC) in Los Angeles. Investors will be watching for new details—timing on orders, capacity updates, anything on the 2027 delivery window that analysts have been banking on.

Marcin Frąckiewicz

Marcin Frąckiewicz is the CEO of TS2 Space and a longtime technology entrepreneur focused on telecommunications, satellite communications and digital innovation. A graduate of the Warsaw School of Economics (SGH), he writes about space technology, artificial intelligence and publicly traded technology companies. His analysis covers major market trends, emerging technologies and the businesses shaping the future of the global economy.

Stock Market Today

  • Novartis Wins UK High Court Case to Keep Entresto SPC, Stopping Accord Generic Bid
    August 14, 2026, 8:44 AM EDT. Novartis kept its UK Supplementary Protection Certificate for Entresto after a High Court ruling, which holds off Accord Healthcare from launching a generic until at least 2028. The SPC, set to run past the original patent's end in January 2023, covers valsartan and sacubitril in combination. Judge Richard Meade threw out Accord's challenge to the SPC after the exclusivity period lapses in November 2026, finding the SPC both valid and infringed. The result lines up with a similar Dutch court decision backing the SPC. Novartis used Bristows and Three New Square in the case.